Drug intelligence / Profile preview

Evalstotug

Development stage: Phase 2
Lead developer: BioAtla
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Evalstotug is a conditionally active biologic (CAB) anti-CTLA-4 monoclonal antibody developed by BioAtla. It is designed to block the interaction of CTLA-4 with its ligands, primarily in the acidic tumor microenvironment, which reduces off-tumor immune-related adverse events and enhances host immunity. Evalstotug is being investigated for several solid tumor indications, including melanoma and non-small cell lung cancer, often in combination with PD-1 inhibitors.

Other names: CAB-CTLA-4CAB-CTLA4CAB-CTLA 4

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on Evalstotug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evalstotug.

Explore the full profile